The Journal of Urology
Volume 183, Issue 2 , Pages 598-602 , February 2010

Prospective Randomized Evaluation of Periureteral Botulinum Toxin Type A Injection for Ureteral Stent Pain Reduction

Received 21 June 2009

References 

  1. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980;212:16
  2. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342:665
  3. Schulte-Baukloh H, Michael T, Sturzebecher B, et al. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003;44:139
  4. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347
  5. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871
  6. Pollard SG, Macfarlane R. Symptoms arising from Double-J ureteral stents. J Urol. 1988;139:37
  7. Duvdevani M, Chew BH, Denstedt JD. Minimizing symptoms in patients with ureteric stents. Curr Opin Urol. 2006;16:77
  8. Joshi HB, Stainthorpe A, MacDonagh RP, et al. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169:1065
  9. Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol. 2009;181:170
  10. Irani J, Siquier J, Pires C, et al. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int. 1999;84:276
  11. Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol. 2004;14:111
  12. Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008;22:651
  13. Dickson E, Shevky R. Studies on manner in which the toxin of clostridium botulinum acts upon the body. J Exp Med. 1923;37:711
  14. Carpenter FG. Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats. J Physiol. 1967;188:1
  15. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196
  16. Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59:511
  17. Al-Kandari AM, Al-Shaiji TF, Shaaban H, et al. Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J Endourol. 2007;21:698
  18. Breau RH, Norman RW. Optimal prevention and management of proximal ureteral stent migration and remigration. J Urol. 2001;166:890
  19. Pilcher JM, Patel U. Choosing the correct length of ureteric stent: a formula based on the patient's height compared with direct ureteric measurement. Clin Radiol. 2002;57:59
  20. Lennon GM, Thornhill JA, Sweeney PA, et al. ‘Firm’ versus ‘soft’ double pigtail ureteric stents: a randomised blind comparative trial. Eur Urol. 1995;28:1
  21. Lennon GM, Thornhill JA, Grainger R, et al. Double pigtail ureteric stent versus percutaneous nephrostomy: effects on stone transit and ureteric motility. Eur Urol. 1997;31:24
  22. Joshi HB, Chitale SV, Nagarajan M, et al. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J Urol. 2005;174:2303
  23. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125
  24. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106
  25. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35

 Study received institutional review board approval.

 For another article on a related topic see page 765.

PII: S0022-5347(09)02656-1

doi: 10.1016/j.juro.2009.10.021

The Journal of Urology
Volume 183, Issue 2 , Pages 598-602 , February 2010

Article Tools

* Image Usage & Resolution